Results 101 to 110 of about 149 (136)
Head &Neck, EarlyView.ABSTRACT Background The NTRK fusion gene is detected in most salivary gland secretory carcinomas. While tropomyosin receptor kinase (TRK) inhibitors are used for various solid tumors with the fusion gene, there are no reports regarding TRK inhibitor use for unresectable parotid gland carcinomas that subsequently shrink and become resectable.
Arisa Nagano +11 more
wiley +1 more source
Nanotechnology in brain cancer treatment: The role of gold nanoparticles as therapeutic enhancers
Ibrain, EarlyView.This review highlights the potential of gold nanoparticles (AuNPs) in overcoming the blood‐brain barrier (BBB) to improve brain tumor treatment. By enabling targeted drug delivery and enhancing therapies like radiotherapy, phototherapy, and chemotherapy, AuNPs offer a promising approach for safer, more effective treatments of glioblastoma and other ...
Simona Tarantino +4 more
wiley +1 more source
Epigenomics‐guided precision oncology: Chromatin variants in prostate tumor evolution
International Journal of Cancer, EarlyView.Abstract Prostate cancer is a common malignancy that in 5%–30% leads to treatment‐resistant and highly aggressive disease. Metastasis‐potential and treatment‐resistance is thought to rely on increased plasticity of the cancer cells—a mechanism whereby cancer cells alter their identity to adapt to changing environments or therapeutic pressures to create
Kira Furlano +6 more
wiley +1 more source
Exosomes, autophagy, and cancer: A complex triad
International Journal of Cancer, EarlyView.Abstract Cancer remains one of the leading causes of death worldwide. Despite remarkable progress in prevention, diagnosis, and therapy, the incidence of certain types of cancer persists, urging the identification of clinically relevant biomarkers and the development of novel therapeutic strategies to improve clinical outcomes and overcome treatment ...
María Guerra‐Andrés +2 more
wiley +1 more source
Therapeutic targeting of chromatin alterations in leukemia and solid tumors
International Journal of Cancer, EarlyView.Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner +7 more
wiley +1 more source
International Journal of Cancer, EarlyView.What's New? About half of penile squamous cell carcinomas are causally associated with inflammatory conditions such as lichen sclerosus (LSc), but few large‐scale studies have assessed the risk of penile cancer in men with LSc. Here, the authors conducted a large nationwide study in Denmark to estimate the risk of penile and non‐penile cancer in men ...
Marianne Gardar Stærk +5 more
wiley +1 more source
Blood‐based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy
International Journal of Cancer, EarlyView.Abstract Soft tissue sarcoma (STS) is a rare and heterogeneous cancer, comprising approximately 1% of all adult cancers and 7%–15% of all childhood cancers. In the advanced stages, chemotherapy remains the standard‐of‐care, but efficacy is limited, with a response rate of 15%–30%, and responses are often short‐lived, with median progression‐free ...
Brie‐Anne Mannah +2 more
wiley +1 more source
IJU Case Reports, EarlyView.Introduction We encountered a case of acute obstructive pyelonephritis caused by bleeding from a renal pelvis cancer that was successfully treated by laparoscopic nephrectomy. Case presentation An 88‐year‐old woman with fever of 40.2°C and right back pain associated with hematuria due to a right renal pelvic tumor.
Masato Yanagi +8 more
wiley +1 more source
IJU Case Reports, EarlyView.ABSTRACT Introduction Hypercalcemia is a poor prognostic factor in advanced cancer. Case Presentation A patient with advanced clear cell renal carcinoma with hypercalcemia was treated with nivolumab+ipilimumab combination therapy. Treatment was discontinued after 4 months due to renal dysfunction.
Masataka Abe +9 more
wiley +1 more source